To market, to market - 2002

被引：20

作者：

Boyer-Joubert, C ^{[1
]}

Lorthiois, E ^{[1
]}

Moreau, F ^{[1
]}

机构：

[1] Pfizer Global Res & Dev, Fresnes, France

来源：

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 38 | 2003年 / 38卷

关键词：

D O I：

10.1016/S0065-7743(03)38034-0

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：347 / 374

页数：28

共 162 条

[11] Efficient one-pot synthesis of the 2-aminocarbonylpyrrolidin-4-ylthio-containing side chain of the new broad-spectrum carbapenem antibiotic ertapenem [J].

Brands, KMJ ;

Jobson, RB ;

Conrad, KM ;

Williams, JM ;

Pipik, B ;

Cameron, M ;

Davies, AJ ;

Houghton, PG ;

Ashwood, MS ;

Cottrell, IF ;

Reamer, RA ;

Kennedy, DJ ;

Dolling, UH ;

Reider, PJ .

JOURNAL OF ORGANIC CHEMISTRY, 2002, 67 (14) :4771-4776

[12]

BURKE A, 2002, DRUG TODAY, V38, P195

[13] Escitalopram [J].

Burke, WJ .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (10) :1477-1486

[14] Parecoxib - A viewpoint by Daniel Carr [J].

Carr, D .

DRUGS, 2001, 61 (08) :1142-1142

[15] Ezetimibe -: Hypolipidemic cholesterol absorption inhibitor [J].

Castañer, RM ;

Sorbera, LA ;

Castañer, J .

DRUGS OF THE FUTURE, 2000, 25 (07) :679-685

[16] Voriconazole: A second-generation triazole [J].

Chandrasekar, PH ;

Manavathu, E .

DRUGS OF TODAY, 2001, 37 (02) :135-148

[17]

Chattaraj Sarat C, 2002, Curr Opin Investig Drugs, V3, P582

[18] In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663) [J].

Chauret, N ;

Yergey, JA ;

Brideau, C ;

Friesen, RW ;

Mancini, J ;

Riendeau, D ;

Silva, J ;

Styhler, A ;

Trimble, LA ;

Nicoll-Griffith, DA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (08) :1059-1062

[19] Parecoxib (parecoxib sodium) [J].

Cheer, SM ;

Goa, KL .

DRUGS, 2001, 61 (08) :1133-1141

[20] Radioimmunotherapy of non-Hodgkin lymphomas [J].

Cheson, BD .

BLOOD, 2003, 101 (02) :391-398

← 1 2 3 4 5 6 7 8 9 10 →